A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
收藏DataCite Commons2025-12-03 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012005/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma \[mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) \]compared to that achieved with therapy in the control arm.
提供机构：
Vivli
创建时间：
2025-12-02
